2VSA Stock Chart & Stats
€5.27
€0.04(0.68%)
At close: 4:00 PM EDT
€5.27
€0.04(0.68%)
Day’s Range― - ―
52-Week Range€2.88 - €9.00
Previous CloseN/A
Volume15.00
Average Volume (3M)251.00
Market Cap
€550.02M
Enterprise Value€330.42
Total Cash (Recent Filing)€136.35M
Total Debt (Recent Filing)€84.33M
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Nov 11, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.46
Shares Outstanding90,563,440
10 Day Avg. Volume261
30 Day Avg. Volume251
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)9.35
Price to Sales (P/S)17.31
P/FCF Ratio-3.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.46Price Target Upside136.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.38
Revenue Forecast (FY)€89.40M
Bulls Say, Bears Say
Bulls Say
Commercial GrowthRising product revenue and broader prescribing across academic and community practices indicate improving commercial execution. Continued adoption could help the LGSOC franchise fund its operations and reduce reliance on external capital over time.
Pipeline ExpansionAdvancing VS-7375 across pancreatic, colorectal and lung cancer broadens Verastem’s potential revenue base beyond its current franchise. Fast Track status and planned pivotal development could accelerate regulatory interaction if efficacy and safety mature.
Liquidity RunwayThe enlarged liquidity position gives Verastem time to support commercialization and advance clinical programs toward important readouts. A longer runway lowers near-term funding pressure and preserves strategic flexibility while revenue scales.
Bears Say
Large Losses And Cash BurnVerastem remains far from self-funding, with losses and cash consumption substantially exceeding its current revenue base. Unless commercial growth and cost leverage improve, continued investment in development and launch activities will require additional capital.
Financing LeverageProduct-linked financing strengthens liquidity but adds claims on future revenue and substantially encumbers company assets. These obligations may limit financial flexibility and leave less cash available for reinvestment if commercialization underperforms.
Clinical And Regulatory RiskThe pipeline’s value depends on proving durable efficacy, manageable tolerability and regulatory differentiation in crowded RAS-driven oncology markets. GI events, dose management and evolving FDA standards could weaken adherence, trial outcomes or approval prospects.
Verastem News
2VSA FAQ
What was Verastem’s price range in the past 12 months?
Verastem lowest stock price was €2.88 and its highest was €9.00 in the past 12 months.
What is Verastem’s market cap?
Verastem’s market cap is €550.02M.
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is Nov 11, 2026 which is in 76 days.
How were Verastem’s earnings last quarter?
Verastem released its earnings results on Aug 06, 2026. The company reported -€0.303 earnings per share for the quarter, beating the consensus estimate of -€0.373 by €0.069.
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem does not currently pay dividends.
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -0.38.
How many shares outstanding does Verastem have?
Verastem has 90,563,440 shares outstanding.
What happened to Verastem’s price movement after its last earnings report?
Verastem reported an EPS of -€0.303 in its last earnings report, beating expectations of -€0.373. Following the earnings report the stock price went up 7.393%.
Which hedge fund is a major shareholder of Verastem?
Currently, no hedge funds are holding shares in DE:2VSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Verastem Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€12.46 (136.49% Upside)
€12.46 (136.49% Upside)
Blogger Sentiment
Bullish
DE:2VSA Sentiment 67%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth €95.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.22%
Trailing 12-Months
Company Description
Verastem
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
2VSA Company Deck
2VSA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial positive momentum: commercial rebound with $25.1M in product revenue, strengthened liquidity via a $50M draw and $15M milestone (pro forma cash $201.4M), improved non-GAAP loss versus prior year, and rapid clinical progress for VS-7375 (enrollment completed in expansions, Fast Track for NSCLC, three Phase II studies initiated and an October data update anticipated). Notable risks remain — the company is still loss-making with high R&D spend, relies on financing to bridge to readouts, has limited prescription visibility, faces tolerability and dose-management operational challenges, and navigates a competitive/regulatory landscape. On balance, the material commercial and clinical achievements and improved financial cushion outweigh the outstanding challenges.View all DE:2VSA earnings summaries2VSA Stock 12 Month Forecast
Average Price Target
€12.46
▲(136.49% Upside)
Technical Analysis
Puma Biotechnology
―
CytomX Therapeutics
―
Arvinas Holding Company
―
Allogene Therapeutics
―
BridgeBio Oncology Therapeutics
―